Imatinib Response in Patients With Chronic Myeloid Leukemia (CML) in Function of Abl Polymorphisms

Inclusion Criteria: * The patient must have given his/her informed and signed consent * The patient must be insured or beneficiary of a health insurance plan Inclusion Criteria for all CML patients * Patients diagnosed with CML * Treatment with Imatinib in first-line monotherapy and this for at least 12 months * RNA and / or cDNA used for diagnosis correctly stored in the biobank Inclusion Criteria for CML patients already having undergone a follow-up visit at 12 months * RNA and / or cDNA used for diagnosis/follow-up correctly stored in the biobank * Cytogenetic results are available * Absence of ITK mutation for the primary resistance subgroup * Validated compliance Inclusion Criteria for the optimal response group: * bcr-abl typing is less than 0.1% at 12 months Inclusion criteria for the primary resistance group * bcr-abl typings is \>1% and/or Philadelphia+ is greater than 0 Inclusion Criteria for the control population * Absence of hematologic malignancy Exclusion Criteria: * The patient is participating in another study * The patient is in an exclusion period determined by a previous study * The patient is under judicial protection, under tutorship or curatorship * The patient refuses to sign the consent * It is impossible to correctly inform the patient * The patient is pregnant, parturient, or breastfeeding * The patient has a contraindication for a treatment used in this study Exclusion Criteria for CML patients already having undergone a follow-up visit at 12 months * Known or suspected cause for resistance (dose reduced due to intolerance, digestive disease responsible for malabsorption ...) Exclusion Criteria for the control population * History or suspicion of hemopathy